799 reports of this reaction
1.6% of all MYCOPHENOLIC ACID reports
#17 most reported adverse reaction
CYTOMEGALOVIRUS INFECTION is the #17 most commonly reported adverse reaction for MYCOPHENOLIC ACID, manufactured by Novartis Pharmaceuticals Corporation. There are 799 FDA adverse event reports linking MYCOPHENOLIC ACID to CYTOMEGALOVIRUS INFECTION. This represents approximately 1.6% of all 51,116 adverse event reports for this drug.
MYCOPHENOLIC ACID has an overall safety score of 88 out of 100. Patients taking MYCOPHENOLIC ACID who experience cytomegalovirus infection should discuss this symptom with their healthcare provider to determine whether it may be related to their medication and what alternatives may be available.
CYTOMEGALOVIRUS INFECTION is a less commonly reported adverse event for MYCOPHENOLIC ACID, but still significant enough to appear in the safety profile.
In addition to cytomegalovirus infection, the following adverse reactions have been reported for MYCOPHENOLIC ACID:
The following drugs have also been linked to cytomegalovirus infection in FDA adverse event reports:
CYTOMEGALOVIRUS INFECTION has been reported as an adverse event in 799 FDA reports for MYCOPHENOLIC ACID. This does not prove causation, but indicates an association observed in post-market surveillance data.
CYTOMEGALOVIRUS INFECTION accounts for approximately 1.6% of all adverse event reports for MYCOPHENOLIC ACID, making it a notable side effect.
If you experience cytomegalovirus infection while taking MYCOPHENOLIC ACID, contact your healthcare provider. They can evaluate whether the symptom is related to your medication and discuss potential adjustments to your treatment plan. Do not stop taking prescribed medication without consulting your doctor.